Advanced Search:
Equity Index

GLPG.AS - GALAPAGOS

€26.98  -0.26 (-0.95%)

Updated: 08:02 May 8, 2024 EST

Next Session's AI Forecast

99%

Avg. Accuracy (AI)

€26.38

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€25.42

GALAPAGOS's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

GALAPAGOS - HISTORICAL DATA 6M

  • Last price

    €26.98

  • Daily change

    €-0.26

  • Previous Close

    €27.24

  • Last Updated

    08:02 May 8, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.62 -0.42 -0.5 -0.21 -0.14

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.36 1.1 1.2 1.09 1.16

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
75% 87.18% 26.15% 6.63%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
27.09 0.26% 27.02 -4.93% 28.42 -14.4% 33.2

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.41 55.56 0.8 29.08

GALAPAGOS Technical Analysis News

GALAPAGOS

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 1123
Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate Governance

Galapagos NV’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 4; Compensation: 10.

GALAPAGOS'S HOLDERS RANK

List of holders with stock participation in GALAPAGOS.

Holder Rank Holder Shares Date Reported % Out Value